Patent · US Active

Crimean-Congo hemorrhagic fever virus vaccine

US9474796B2 · kind B2 · utility

0Cited by

1References

17Claims

0Family size

Assignees

The United States of America, as represented by the Secretary, Department of Health and Human Services · US
Colorado Seminary Which Owns and Operates The University of Denver · US

Inventors

Eric Bergeron · Montréal, CA
Scott Dusan Pegan · Oak Park, US
Stuart T. Nichol · Atlanta, US
Michelle Kay Deaton · Denver, US

Key dates

Filing date	Mar 14, 2013
Grant date	Oct 25, 2016
Priority date	—
Expiry date	Mar 16, 2034

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The genetically modified hemorrhagic fever virus of this invention possesses a viral ovarian tumor protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags that the human organism uses to label proteins for removal. Unlike complete knockout strains, the modified virus retains enough activity for replication in a human cell line. This creates an immunogenic and non-pathogenic virus that can be used as an effective live vaccine agent.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.